Insilico announces the expansion of its oncology pipelines and delivers the new generation FGFR2/3 inhibitor
- The nomination of the new generation of FGFR2/3 inhibitor for the treatment of tissue-agnostic solid tumors, bringing the total number of PCCs nominated by Insilico in 2023 to six.
- ISM8001 is an oral, highly selective, covalent inhibitor that demonstrated superior potency in multiple FGFR2/3-driven efficacy models, and also in gatekeeper and molecular brake mutant resistant models.
- The program once again demonstrates Insilico's ability to efficiently generate novel molecules with high quality that are currently available for partnering.
Insilico Medicine ("Insilico"), a generative artificial intelligence (AI)-driven clinical-stage drug discovery ...








